Synlogic Announces Initiation of Phase 1 Study of SYNB1934, a Next-Generation Strain for the Treatment of Phenylketonuria (PKU)
"We are delighted to have so quickly advanced SYNB1934 into the clinic, strengthening our PKU portfolio and our potential to provide a meaningful new therapeutic option for patients living with PKU," said
"SYNB1618 and SYNB1934 are orally administered Synthetic Biotic medicines intended to address the needs of PKU patients of all age groups and genotypes through the consumption of Phe in the gastrointestinal tract," said
SYNB1934 is a strain that has been evolved from SYNB1618, which is currently being evaluated in a Phase 2 clinical study. SYNB1934 has the potential to provide increased phenylalanine (Phe) lowering efficacy for patients living with PKU. Preclinical in vivo and in vitro studies demonstrated a greater than 2-fold improvement in the ability of SYNB1934 to consume and break down Phe compared to SYNB1618, based on production of Phe metabolites.
The Phase 1 multiple ascending dose study of SYNB1934 will evaluate the safety, tolerability and Phe consumption activity of SYNB1934, including a head-to-head comparison with SYNB1618 in healthy volunteers using biomarkers of Phe consumption. Based on the data from the head-to-head comparison, as well as results of the ongoing Phase 2 study of SYNB1618 in patients with PKU,
Data on the solid oral formulation of SYNB1618 was presented at the
Patients can learn more about the SynPheny-1 study (NCT04534842) by visiting https://pkuresearchstudy.com. More information about
Phenylketonuria (PKU) is an inherited metabolic disease that manifests at birth and is marked by an inability to break down Phe, an amino acid that is commonly found in many foods. Left untreated, high levels of Phe become toxic and can lead to serious neurological and neuropsychological problems affecting the way a person thinks, feels, and acts. Due to the seriousness of these symptoms, infants are screened at birth in many countries to ensure early diagnosis and treatment to avoid intellectual disability and other complications.
Synlogic™ is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering,
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to
View original content:https://www.prnewswire.com/news-releases/synlogic-announces-initiation-of-phase-1-study-of-synb1934-a-next-generation-strain-for-the-treatment-of-phenylketonuria-pku-301334191.html
Media Contact: Christen Baglaneas, Synlogic, Inc., Phone: 617-401-9152, Email: firstname.lastname@example.org; Investor Contact: Daniel Rosan, Synlogic, Inc., Phone: 617-401-9152, Email: email@example.com